Sanofi (NASDAQ:SNY) Position Trimmed by First Eagle Investment Management LLC

First Eagle Investment Management LLC trimmed its holdings in shares of Sanofi (NASDAQ:SNY) by 0.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 328,974 shares of the company’s stock after selling 3,115 shares during the period. First Eagle Investment Management LLC’s holdings in Sanofi were worth $15,866,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. Aviso Financial Inc. boosted its holdings in Sanofi by 1.1% during the fourth quarter. Aviso Financial Inc. now owns 41,837 shares of the company’s stock worth $2,018,000 after buying an additional 457 shares in the last quarter. JPL Wealth Management LLC bought a new stake in Sanofi during the fourth quarter worth approximately $2,277,000. HBK Sorce Advisory LLC boosted its holdings in Sanofi by 10.1% during the fourth quarter. HBK Sorce Advisory LLC now owns 4,267 shares of the company’s stock worth $206,000 after buying an additional 391 shares in the last quarter. Avantax Advisory Services Inc. boosted its holdings in Sanofi by 23.4% during the fourth quarter. Avantax Advisory Services Inc. now owns 44,507 shares of the company’s stock worth $2,147,000 after buying an additional 8,439 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its stake in Sanofi by 30.7% in the 4th quarter. Farther Finance Advisors LLC now owns 3,739 shares of the company’s stock worth $180,000 after purchasing an additional 878 shares during the period. 14.04% of the stock is currently owned by institutional investors.

Sanofi Trading Up 0.1 %

NASDAQ SNY opened at $57.75 on Friday. The firm’s 50 day moving average price is $53.46 and its two-hundred day moving average price is $52.85. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. Sanofi has a twelve month low of $45.22 and a twelve month high of $60.12. The stock has a market cap of $146.56 billion, a price-to-earnings ratio of 23.19, a PEG ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Equities analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on SNY. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $60.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.